Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Fate Therapeutics's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F6T vs IMRX, NWBO, FHTX: OCF Margin % Comparison
For the Biotechnology subindustry, Fate Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fate Therapeutics OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics (FRA:F6T) has a OCF Margin % of -1,125.68% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Fate Therapeutics and its competitors. According to the industry distribution chart, Fate Therapeutics ranks #802 out of 956 companies in the Biotechnology industry, placing it in the top 83.9%.
Is Fate Therapeutics' OCF Margin % too high?
Fate Therapeutics' current OCF Margin % is -1,125.68%. Based on the distribution chart, Fate Therapeutics ranks #802 out of 956 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fate Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fate Therapeutics' OCF Margin % compare to IMRX and NWBO?
According to the Biotechnology industry distribution chart, Fate Therapeutics ranks #802 out of 956 companies for OCF Margin %. This places Fate Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Fate Therapeutics and its competitors. Fate Therapeutics's current OCF Margin % is -1,125.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fate Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fate Therapeutics (FRA:F6T) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €2.11 — trading 224% above its estimated fair value. The current OCF Margin % is -1,125.68%. Fate Therapeutics' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Fate Therapeutics (FRA:F6T), the current OCF Margin % is -1,125.68% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fate Therapeutics (FRA:F6T) Overvalued in 2026?
Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued.
The current stock price of €2.11 is trading 224% above its estimated GF Value™ of €0.65.
GuruFocus considers Fate Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:F6T:
OCF Margin %: -1,125.68%
GF Value™: €0.65 vs. price of €2.11 (224% above fair value)
No single metric tells the full story. See the FRA:F6T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
33GF Score
Get the complete analysis for FRA:F6T
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F6T has been successfully added to your 
